Can Ozempic Cause Gastroparesis? What the Evidence Shows

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Guidance to Targeted Pharmacovigilance

If you're taking Ozempic and experiencing persistent nausea, bloating, or abdominal pain, you may wonder whether the medication is causing delayed gastric emptying. For decades, pharmacovigilance systems have monitored drug safety through post-marketing surveillance and clinical studies. This page examines the current evidence on whether Ozempic can cause gastroparesis, including FDA communications and what the science can and cannot prove.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. It presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which a radiolabeled meal leaves the stomach. The condition can lead to nutritional deficiencies, weight loss, and impaired quality of life. In the context of Ozempic, the prescribing information reports that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific rates for nausea were 6.1% for placebo, 15.8% for Ozempic 0.5 mg, and 20.3% for Ozempic 1 mg; vomiting rates were 2.3%, 5.0%, and 9.2%, respectively; and diarrhea rates were 1.9%, 8.5%, and 8.8%, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Abdominal pain and constipation were also reported at higher frequencies in Ozempic-treated patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, raising the question of whether Ozempic can induce or exacerbate this condition.

Pharmacology of Ozempic and Mechanistic Pathways to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its prescribing information documents a range of gastrointestinal adverse reactions, which are among the most commonly reported side effects. The mechanistic pathways linking Ozempic to gastroparesis involve the drug's effect on gastric motility. GLP-1 receptor agonists slow gastric emptying through activation of GLP-1 receptors in the gastrointestinal tract and central nervous system. This delay in gastric emptying is a known pharmacodynamic effect of semaglutide and is thought to contribute to its glucose-lowering efficacy by reducing postprandial glucose excursions. However, excessive or prolonged slowing of gastric emptying can lead to symptoms consistent with gastroparesis. The prescribing information lists pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, hypersensitivity, and acute gallbladder disease as serious adverse reactions, but does not explicitly list gastroparesis as a separate warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The most common adverse reactions reported in ≥5% of Ozempic-treated patients include nausea, vomiting, diarrhea, abdominal pain, and constipation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these symptoms are not pathognomonic for gastroparesis, they are consistent with its clinical presentation.

Risk Considerations: Warning Adequacy and Causation

Risk considerations for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information does not contain a specific warning for gastroparesis, but it does describe gastrointestinal adverse reactions as common and notes that more patients receiving Ozempic discontinued treatment due to gastrointestinal adverse reactions compared to placebo: 3.1% for Ozempic 0.5 mg and 3.8% for Ozempic 1 mg versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that gastrointestinal symptoms can be severe enough to warrant discontinuation. For patients who develop persistent nausea, vomiting, or abdominal pain, clinicians should consider the possibility of gastroparesis and evaluate accordingly. Causation-related considerations involve the temporal relationship between Ozempic exposure and symptom onset. The prescribing information indicates that gastrointestinal adverse reactions predominantly occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), which may help establish a timeline. However, symptoms can also emerge later in treatment, and individual susceptibility may vary. In clinical trials, the types and frequency of common adverse reactions in a 40-week study with 959 patients treated with Ozempic 1 mg or 2 mg were similar to those in earlier trials, with no new safety signals identified (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that the gastrointestinal effects are consistent across different dosing regimens. For patients who experience symptoms suggestive of gastroparesis, the timeline between exposure and documented harm is critical. The prescribing information does not provide specific data on the duration of treatment before onset of gastroparesis, but the dose-escalation phase is a period of heightened risk. Once symptoms develop, they may persist or resolve upon dose adjustment or discontinuation. The lack of a specific warning for gastroparesis in the prescribing information may lead to underrecognition of this potential adverse effect. Clinicians should be vigilant for symptoms that do not resolve with standard management of nausea or vomiting and consider diagnostic testing for gastroparesis. Patients should be informed about the possibility of gastrointestinal side effects and advised to report persistent symptoms.

Summary and Clinical Implications

In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, abdominal pain, and constipation, which overlap with the clinical presentation of gastroparesis. The drug's mechanism of action, which includes delayed gastric emptying, provides a plausible pathway for inducing gastroparesis. The prescribing information does not contain a specific warning for gastroparesis, but the frequency and severity of gastrointestinal adverse reactions are documented. Causation considerations include the temporal relationship during dose escalation and the potential for symptom persistence. Affected patients should be evaluated for gastroparesis if symptoms are severe or prolonged. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning regarding Ozempic and gastroparesis?

The prescribing information for Ozempic does not contain a specific warning for gastroparesis, but it documents a high incidence of gastrointestinal adverse reactions such as nausea, vomiting, diarrhea, abdominal pain, and constipation, which overlap with gastroparesis symptoms. The FDA has not issued a separate warning for gastroparesis, but the drug's label notes that gastrointestinal adverse reactions are common and can lead to discontinuation.

Can Ozempic cause gastroparesis?

There is a plausible mechanistic link: Ozempic slows gastric emptying through GLP-1 receptor activation, which can lead to symptoms consistent with gastroparesis. Clinical trials show high rates of gastrointestinal side effects, and some patients may develop persistent symptoms that meet criteria for gastroparesis. However, the prescribing information does not explicitly list gastroparesis as an adverse reaction, and causation requires individual assessment of temporal relationship and exclusion of other causes.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.